[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

4 clusters · 9 sources · 41 days · First seen · Last updated

Retatrutide investigational drug development and safety

Overview

Retatrutide, an investigational synthetic peptide developed by Eli Lilly (also known by the code LY3437943), is being studied for its metabolic potential in managing food regulation, sugar, and weight. As a triple receptor agonist, it mimics natural gut and pancreatic hormones by acting on GIP, GLP-1, and glucagon receptors simultaneously. While large-scale human results were published in the New England Journal of Medicine in 2023, the compound remains in the investigational stage and lacks regulatory approval for human use.

Concerns have intensified regarding the use of unauthorized versions of the drug. The FDA has stated the drug has not been found safe or effective for any condition, and federal law prohibits pharmacies from compounding it. Reports indicate two deaths linked to products allegedly containing the substance: one involving severe heart arrhythmia and another involving dehydration, malnutrition, and cardiac arrest. Much of this unregulated supply is traced to Chinese factories that advertise on social media and ship products via mail for cryptocurrency.

Data from U.S. poison control centers shows a significant increase in exposure cases, rising from 460 in the previous quarter to 862 in the three months ending in September. Furthermore, an AI analysis of approximately 150,000 Reddit posts by University of Pennsylvania researchers uncovered unexpected symptom patterns. Notably, increased appetite was a common complaint among users, which contradicts the drug’s intended purpose of appetite suppression and differs from the digestive issues primarily identified in Phase 2 clinical trials.

Regulatory warnings have expanded internationally. The Saudi Food and Drug Authority (SFDA) issued an official warning, noting the drug is not registered with the SFDA and its commercial distribution is illegal. The SFDA cautioned that products sold via unofficial channels may contain “unknown ingredients, harmful contaminants, or incorrect dosages.”

Entities

Eli Lilly · Retatrutide · Harvard University · Retatrutide · Saudi Food and Drug Authority

Timeline

  1. [HEALTH] 2 sources
    Saudi FDA warns against unapproved use of Retatrutide

    The Saudi Food and Drug Authority warns that Retatrutide is not approved for use and remains in clinical trials, posing serious health risks if purchased through unverified sources.

  2. [HEALTH] 2 sources
    Retatrutide: Unapproved weight-loss drug linked to deaths and unexpected side effects

    Unapproved retatrutide, an experimental weight-loss drug, is linked to reported deaths and unexpected side effects like increased appetite according to new AI-driven research.

  3. [HEALTH] 2 sources
    Retatrutide weight-loss drug linked to two deaths in U.S

    Two deaths in the U.S. linked to unauthorized versions of the experimental weight-loss drug Retatrutide have prompted FDA scrutiny and warnings from Eli Lilly regarding counterfeit products.

  4. [HEALTH] 3 sources
    Retatrutide investigational peptide undergoes metabolic research

    Retatrutide (LY3437943) is an investigational triple receptor agonist developed by Eli Lilly for metabolic research, currently undergoing clinical evaluation for weight and sugar management.

Sources

alsadaranews.com · alsaudi.news · alwakeelnews.com · dailycallernewsfoundation.org · jehat.net · radiologykey.com · satanic-kindred.org · sciencedaily.com · socialnews.xyz

This summary has been updated 2 times: see revision history